<!DOCTYPE html PUBLIC "-//W3C//DTD XHTML 1.0 Transitional//EN" "http://www.w3.org/TR/xhtml1/DTD/xhtml1-transitional.dtd">
<html xmlns="http://www.w3.org/1999/xhtml" xml:lang="en" lang="en" dir="ltr">
  <head>
    <meta http-equiv="Content-Type" content="text/html; charset=UTF-8" />
    		<meta name="keywords" content="ABVD,2006,Acute leukemia,Adriamycin,Alkylating agent,Allergic reaction,Alopecia,Anemia,Antiemetic,Benzodiazepine,Bleomycin" />
		<link rel="shortcut icon" href="/favicon.ico" />
		<link rel="search" type="application/opensearchdescription+xml" href="/w/opensearch_desc.php" title="Wikipedia (English)" />
		<link rel="copyright" href="../../../COPYING.html" />
    <title>ABVD - Wikipedia, the free encyclopedia</title>
    <style type="text/css">/*<![CDATA[*/ @import "../../../skins/htmldump/main.css"; /*]]>*/</style>
    <link rel="stylesheet" type="text/css" media="print" href="../../../skins/common/commonPrint.css" />
    <!--[if lt IE 5.5000]><style type="text/css">@import "../../../skins/monobook/IE50Fixes.css";</style><![endif]-->
    <!--[if IE 5.5000]><style type="text/css">@import "../../../skins/monobook/IE55Fixes.css";</style><![endif]-->
    <!--[if IE 6]><style type="text/css">@import "../../../skins/monobook/IE60Fixes.css";</style><![endif]-->
    <!--[if IE]><script type="text/javascript" src="../../../skins/common/IEFixes.js"></script>
    <meta http-equiv="imagetoolbar" content="no" /><![endif]-->
    <script type="text/javascript" src="../../../skins/common/wikibits.js"></script>
    <script type="text/javascript" src="../../../skins/htmldump/md5.js"></script>
    <script type="text/javascript" src="../../../skins/htmldump/utf8.js"></script>
    <script type="text/javascript" src="../../../skins/htmldump/lookup.js"></script>
    <script type="text/javascript" src="../../../raw/gen.js"></script>        <style type="text/css">/*<![CDATA[*/
@import "../../../raw/MediaWiki%7ECommon.css";
@import "../../../raw/MediaWiki%7EMonobook.css";
@import "../../../raw/gen.css";
/*]]>*/</style>          </head>
  <body
    class="ns-0">
    <div id="globalWrapper">
      <div id="column-content">
	<div id="content">
	  <a name="top" id="contentTop"></a>
	        <h1 class="firstHeading">ABVD</h1>
	  <div id="bodyContent">
	    <h3 id="siteSub">From Wikipedia, the free encyclopedia</h3>
	    <div id="contentSub"></div>
	    	    	    <!-- start content -->
	    <p><b>ABVD</b> is a <a href="../../../c/h/e/Chemotherapy_regimen.html" title="Chemotherapy regimen">chemotherapy regimen</a> used in the first-line treatment of <a href="../../../h/o/d/Hodgkin%27s_lymphoma.html" title="Hodgkin's lymphoma">Hodgkin's lymphoma</a>. It consists of concurrent treatment with the chemotherapy drugs <a href="../../../a/d/r/Adriamycin.html" title="Adriamycin">adriamycin</a>, <a href="../../../b/l/e/Bleomycin.html" title="Bleomycin">bleomycin</a>, <a href="../../../v/i/n/Vinblastine.html" title="Vinblastine">vinblastine</a> and <a href="../../../d/a/c/Dacarbazine.html" title="Dacarbazine">dacarbazine</a>.</p>
<table id="toc" class="toc" summary="Contents">
<tr>
<td>
<div id="toctitle">
<h2>Contents</h2>
</div>
<ul>
<li class="toclevel-1"><a href="#Indications"><span class="tocnumber">1</span> <span class="toctext">Indications</span></a></li>
<li class="toclevel-1"><a href="#History"><span class="tocnumber">2</span> <span class="toctext">History</span></a>
<ul>
<li class="toclevel-2"><a href="#Development_of_ABVD"><span class="tocnumber">2.1</span> <span class="toctext">Development of ABVD</span></a></li>
</ul>
</li>
<li class="toclevel-1"><a href="#Administration"><span class="tocnumber">3</span> <span class="toctext">Administration</span></a></li>
<li class="toclevel-1"><a href="#Side_effects"><span class="tocnumber">4</span> <span class="toctext">Side effects</span></a>
<ul>
<li class="toclevel-2"><a href="#Acute_side_effects"><span class="tocnumber">4.1</span> <span class="toctext">Acute side effects</span></a></li>
<li class="toclevel-2"><a href="#Delayed_side_effects"><span class="tocnumber">4.2</span> <span class="toctext">Delayed side effects</span></a></li>
</ul>
</li>
<li class="toclevel-1"><a href="#Supportive_care"><span class="tocnumber">5</span> <span class="toctext">Supportive care</span></a>
<ul>
<li class="toclevel-2"><a href="#Antiemetics"><span class="tocnumber">5.1</span> <span class="toctext">Antiemetics</span></a></li>
<li class="toclevel-2"><a href="#Growth_factors"><span class="tocnumber">5.2</span> <span class="toctext">Growth factors</span></a></li>
</ul>
</li>
<li class="toclevel-1"><a href="#References"><span class="tocnumber">6</span> <span class="toctext">References</span></a></li>
<li class="toclevel-1"><a href="#See_also"><span class="tocnumber">7</span> <span class="toctext">See also</span></a></li>
<li class="toclevel-1"><a href="#External_links"><span class="tocnumber">8</span> <span class="toctext">External links</span></a></li>
</ul>
</td>
</tr>
</table>
<p><script type="text/javascript">
//<![CDATA[
 if (window.showTocToggle) { var tocShowText = "show"; var tocHideText = "hide"; showTocToggle(); } 
//]]>
</script><a name="Indications" id="Indications"></a></p>
<h2><span class="editsection">[<a href="../../../a/b/v/ABVD_12ba.html" title="Edit section: Indications">edit</a>]</span> <span class="mw-headline">Indications</span></h2>
<p>As of <a href="../../../2/0/0/2006.html" title="2006">2006</a>, ABVD is widely used as the initial chemotherapy treatment for newly diagnosed Hodgkin's lymphoma. The other chemotherapy regimen that is widely used in this setting is the <a href="../../../s/t/a/Stanford_V_bb98.html" title="Stanford V">Stanford V</a> regimen.</p>
<p><a name="History" id="History"></a></p>
<h2><span class="editsection">[<a href="../../../a/b/v/ABVD_12ba.html" title="Edit section: History">edit</a>]</span> <span class="mw-headline">History</span></h2>
<dl>
<dd><span class="boilerplate seealso"><i>See also: <a href="../../../h/i/s/History_of_cancer_chemotherapy.html" title="History of cancer chemotherapy">History of cancer chemotherapy</a></i></span></dd>
</dl>
<p>Prior to the mid-1960's, advanced-stage Hodgkin disease was treated with single-agent <a href="../../../c/h/e/Chemotherapy.html" title="Chemotherapy">chemotherapy</a>, with fairly dismal long-term survival and cure rates. With advances in the understanding of chemotherapy resistance and the development of <a href="../../../h/i/s/History_of_cancer_chemotherapy.html#Combination_chemotherapy" title="History of cancer chemotherapy">combination chemotherapy</a>, Vincent DeVita and George Canellos at the <a href="../../../n/a/t/National_Cancer_Institute_eeb0.html" title="National Cancer Institute">National Cancer Institute</a> (United States) developed the <a href="../../../m/o/p/MOPP_%28medicine%29_07ad.html" title="MOPP (medicine)">MOPP</a> regimen. This combination of <a href="../../../m/e/c/Mechlorethamine.html" title="Mechlorethamine">mechlorethamine</a>, <a href="../../../v/i/n/Vincristine.html" title="Vincristine">vincristine</a> (Oncovin), <a href="../../../p/r/o/Procarbazine.html" title="Procarbazine">procarbazine</a>, and <a href="../../../p/r/e/Prednisone.html" title="Prednisone">prednisone</a> proved capable of curing almost 70% of patients with advanced-stage Hodgkin's lymphoma.<sup id="_ref-0" class="reference"><a href="#_note-0" title="">[1]</a></sup><sup id="_ref-1" class="reference"><a href="#_note-1" title="">[2]</a></sup></p>
<p>While MOPP was remarkably successful in curing advanced Hodgkin's lymphoma, its <a href="../../../t/o/x/Toxicity.html" title="Toxicity">toxicity</a> remained significant. Aside from <a href="../../../m/y/e/Myelosuppression.html" title="Myelosuppression">bone marrow suppression</a>, frequent side effects included <a href="../../../n/e/u/Neurotoxicity.html" title="Neurotoxicity">nerve injury</a> caused by vincristine and <a href="../../../a/l/l/Allergic_reaction.html" title="Allergic reaction">allergic reactions</a> to procarbazine. Long-term effects were also a concern, as patients were often cured and could expect long survival after chemotherapy. <a href="../../../i/n/f/Infertility.html" title="Infertility">Infertility</a> was a major long-term side effect, and even more seriously, the risk of developing treatment-related <a href="../../../m/y/e/Myelodysplasia.html" title="Myelodysplasia">myelodysplasia</a> or <a href="../../../a/c/u/Acute_leukemia.html" title="Acute leukemia">acute leukemia</a> was increased up to 14-fold in patients who received MOPP.<sup id="_ref-2" class="reference"><a href="#_note-2" title="">[3]</a></sup> These treatment-related <a href="../../../h/e/m/Hematological_malignancies.html" title="Hematological malignancies">hematological malignancies</a> peaked at 5 to 9 years after treatment for Hodgkin's lymphoma, and were associated with a dismally poor prognosis.</p>
<p><a name="Development_of_ABVD" id="Development_of_ABVD"></a></p>
<h3><span class="editsection">[<a href="../../../a/b/v/ABVD_12ba.html" title="Edit section: Development of ABVD">edit</a>]</span> <span class="mw-headline">Development of ABVD</span></h3>
<p>Therefore, alternate regimens were tested in an attempt to avoid <a href="../../../a/l/k/Alkylating_agent.html" title="Alkylating agent">alkylating agents</a> (such as mechlorethamine), which were thought to be responsible for many of the long-term side effects of MOPP. ABVD was developed as a potentially less toxic and more effective alternative to MOPP; initial results with ABVD were published in 1975 by an <a href="../../../i/t/a/Italy.html" title="Italy">Italian</a> group led by Bonadonna.<sup id="_ref-3" class="reference"><a href="#_note-3" title="">[4]</a></sup></p>
<p>A number of trials then compared ABVD to previous regimens for Hodgkin's lymphoma. A large trial by <a href="../../../c/a/l/CALGB_2f57.html" title="CALGB">CALGB</a> suggested that ABVD was superior to MOPP, with a higher rate of overall response, less hematologic toxicity, better relapse-free survival, and better outcomes after relapse in the patients treated with ABVD.<sup id="_ref-4" class="reference"><a href="#_note-4" title="">[5]</a></sup> Later studies confirmed the superiority of ABVD in terms of effectiveness, and also demonstrated that late side effects, such as treatment-related acute leukemia, were less common with ABVD as compared to MOPP.<sup id="_ref-santoro_0" class="reference"><a href="#_note-santoro" title="">[6]</a></sup> Taken together, these results led ABVD to the replacement of MOPP with ABVD in the first-line treatment of Hodgkin's lymphoma.</p>
<p><a name="Administration" id="Administration"></a></p>
<h2><span class="editsection">[<a href="../../../a/b/v/ABVD_12ba.html" title="Edit section: Administration">edit</a>]</span> <span class="mw-headline">Administration</span></h2>
<p>One cycle of ABVD chemotherapy is typically given over 4 weeks, with two doses in each cycle (on day 1 and day 15). All four of the chemotherapy drugs are given <a href="../../../i/n/t/Intravenous.html" title="Intravenous">intravenously</a>. ABVD chemotherapy is usually given in the <a href="../../../o/u/t/Outpatient.html" title="Outpatient">outpatient</a> setting â€” that is, it does not require <a href="../../../h/o/s/Hospitalization.html" title="Hospitalization">hospitalization</a>.</p>
<p>Typical dosages for one 28-day cycle of ABVD are as follows</p>
<ul>
<li><a href="../../../a/d/r/Adriamycin.html" title="Adriamycin">Adriamycin</a> 25 mg/m<sup>2</sup> IV on days 1 and 15</li>
<li><a href="../../../b/l/e/Bleomycin.html" title="Bleomycin">Bleomycin</a> 10 mg/m<sup>2</sup> IV on days 1 and 15</li>
<li><a href="../../../v/i/n/Vinblastine.html" title="Vinblastine">Vinblastine</a> 6 mg/m<sup>2</sup> IV on days 1 and 15</li>
<li><a href="../../../d/a/c/Dacarbazine.html" title="Dacarbazine">Dacarbazine</a> 375 mg/m<sup>2</sup> IV on days 1 and 15</li>
</ul>
<p>The total number of cycles given depends upon the stage of the disease and how well the patient tolerates chemotherapy. Doses may be delayed because of <a href="../../../n/e/u/Neutropenia.html" title="Neutropenia">neutropenia</a>, <a href="../../../t/h/r/Thrombocytopenia.html" title="Thrombocytopenia">thrombocytopenia</a>, or other side effects.</p>
<p><a name="Side_effects" id="Side_effects"></a></p>
<h2><span class="editsection">[<a href="../../../a/b/v/ABVD_12ba.html" title="Edit section: Side effects">edit</a>]</span> <span class="mw-headline">Side effects</span></h2>
<p>In the relative spectrum of cancer chemotherapy, ABVD is not a particularly toxic regimen. Side effects of ABVD can be divided into acute (those occurring while receiving chemotherapy) and delayed (those occurring months to years after completion of chemotherapy). Delayed side effects have assumed particular importance because many patients treated for Hodgkin's lymphoma are cured and can expect long lives after completion of chemotherapy.</p>
<p><a name="Acute_side_effects" id="Acute_side_effects"></a></p>
<h3><span class="editsection">[<a href="../../../a/b/v/ABVD_12ba.html" title="Edit section: Acute side effects">edit</a>]</span> <span class="mw-headline">Acute side effects</span></h3>
<ul>
<li><b>Hair loss</b>, or <a href="../../../a/l/o/Alopecia.html" title="Alopecia">alopecia</a>, is a fairly common but not universal side effect of ABVD. Hair that is lost returns in the months after completion of chemotherapy.</li>
<li><b>Nausea and vomiting</b> can occur with ABVD, although treatments for <a href="../../../c/h/e/Chemotherapy.html#Nausea_and_vomiting" title="Chemotherapy">chemotherapy-induced nausea and vomiting</a> have improved substantially (see <i>Supportive care</i> below).</li>
<li><b>Low blood counts</b>, or <a href="../../../m/y/e/Myelosuppression.html" title="Myelosuppression">myelosuppression</a>, occur about 50% of the time with ABVD. Blood cell <a href="../../../g/-/c/G-CSF_179f.html" title="G-CSF">growth factors</a> are sometimes used to prevent this (see <i>Supportive care</i> below). Blood counts are checked frequently while receiving chemotherapy. Any fever or sign of infection that develops needs to be promptly evaluated; severe infections can develop rapidly in a person with a low <a href="../../../w/h/i/White_blood_cell.html" title="White blood cell">white blood cell</a> count due to chemotherapy.</li>
<li><b>Allergic reactions</b> to bleomycin can occur. A small test dose of bleomycin is often given prior to the first round of ABVD to screen for patients who may be allergic.</li>
</ul>
<p><a name="Delayed_side_effects" id="Delayed_side_effects"></a></p>
<h3><span class="editsection">[<a href="../../../a/b/v/ABVD_12ba.html" title="Edit section: Delayed side effects">edit</a>]</span> <span class="mw-headline">Delayed side effects</span></h3>
<ul>
<li><b>Infertility</b> is probably infrequent with ABVD. Several studies have suggested that, while <a href="../../../s/p/e/Sperm_count.html" title="Sperm count">sperm counts</a> in men decrease during chemotherapy, they return to normal after completion of ABVD.<sup id="_ref-santoro_1" class="reference"><a href="#_note-santoro" title="">[6]</a></sup><sup id="_ref-5" class="reference"><a href="#_note-5" title="">[7]</a></sup><sup id="_ref-6" class="reference"><a href="#_note-6" title="">[8]</a></sup> In women, <a href="../../../f/o/l/Follicle-stimulating_hormone.html" title="Follicle-stimulating hormone">follicle-stimulating hormone</a> levels remained normal while receiving ABVD, suggesting preserved ovarian function. Regardless of these data, fertility options (eg <a href="../../../s/p/e/Sperm_bank.html" title="Sperm bank">sperm banking</a>) should be discussed with an <a href="../../../o/n/c/Oncologist.html" title="Oncologist">oncologist</a> before beginning ABVD therapy.</li>
<li><b>Pulmonary toxicity</b>, or <a href="../../../l/u/n/Lung.html" title="Lung">lung</a> damage, can occur with the use of <a href="../../../b/l/e/Bleomycin.html" title="Bleomycin">bleomycin</a> in ABVD, especially when <a href="../../../r/a/d/Radiation_therapy.html" title="Radiation therapy">radiation therapy</a> to the chest is also given as part of the treatment for Hodgkin's lymphoma. This toxicity develops months to years after completing chemotherapy, and usually manifests as <a href="../../../c/o/u/Cough.html" title="Cough">cough</a> and <a href="../../../d/y/s/Dyspnea.html" title="Dyspnea">shortness of breath</a>. <a href="../../../p/u/l/Pulmonary_function_test.html" title="Pulmonary function test">Pulmonary function tests</a> are often used to assess for bleomycin-related damage to the lungs. One study found bleomycin lung damage in 18% of patients receiving ABVD for Hodgkin's disease.<sup id="_ref-7" class="reference"><a href="#_note-7" title="">[9]</a></sup> Retrospective analyses have questioned whether bleomycin is necessary at all;<sup id="_ref-8" class="reference"><a href="#_note-8" title="">[10]</a></sup> however, at this point it remains a standard part of ABVD.</li>
<li><b>Cardiac toxicity</b>, or <a href="../../../c/a/r/Cardiomyopathy.html" title="Cardiomyopathy">cardiomyopathy</a>, can be a late side effect of <a href="../../../a/d/r/Adriamycin.html" title="Adriamycin">adriamycin</a>. The occurrence of adriamycin-related cardiac toxicity is related to the total lifetime dose of adriamycin, and increases sharply in people who receive a cumulative dose of more than 400 mg/m<sup>2</sup>. Almost all patients treated with ABVD receive less than this dose (for 6 cycles of ABVD, the cumulative adriamycin dose is 300 mg/m<sup>2</sup>); therefore, adriamycin-related cardiac toxicity is very uncommon with ABVD.</li>
<li><b>Secondary malignancies</b>. Patients cured of Hodgkin's lymphoma remain at increased risk of developing other (secondary) cancers. Treatment-related <a href="../../../l/e/u/Leukemia.html" title="Leukemia">leukemias</a> are uncommon with ABVD, especially as compared with MOPP.<sup id="_ref-santoro_2" class="reference"><a href="#_note-santoro" title="">[6]</a></sup> However, one study found a risk of second cancers as high as 28% at 25 years after treatment for Hodgkin's lymphoma, although most of the patients in this study were treated with <a href="../../../m/o/p/MOPP_c55c.html" title="MOPP">MOPP</a> chemotherapy rather than ABVD.<sup id="_ref-9" class="reference"><a href="#_note-9" title="">[11]</a></sup> Many of these second cancers were <a href="../../../l/u/n/Lung_cancer.html" title="Lung cancer">lung cancers</a> or, in women, <a href="../../../b/r/e/Breast_cancer.html" title="Breast cancer">breast cancers</a>, emphasizing the importance of <a href="../../../s/m/o/Smoking_cessation.html" title="Smoking cessation">smoking cessation</a> and regular <a href="../../../p/r/e/Preventive_care.html" title="Preventive care">preventive care</a> after completion of treatment. Radiation and chemotherapy probably both play a role in the development of these secondary malignancies; the exact contribution of chemotherapy such as ABVD can be difficult to tease out.</li>
</ul>
<p><a name="Supportive_care" id="Supportive_care"></a></p>
<h2><span class="editsection">[<a href="../../../a/b/v/ABVD_12ba.html" title="Edit section: Supportive care">edit</a>]</span> <span class="mw-headline">Supportive care</span></h2>
<p><i>Supportive care</i> refers to efforts to prevent or treat side effects of ABVD chemotherapy, and to help patients get through the chemotherapy with the least possible discomfort.</p>
<p><a name="Antiemetics" id="Antiemetics"></a></p>
<h3><span class="editsection">[<a href="../../../a/b/v/ABVD_12ba.html" title="Edit section: Antiemetics">edit</a>]</span> <span class="mw-headline">Antiemetics</span></h3>
<p>Significant advances in <a href="../../../a/n/t/Antiemetic.html" title="Antiemetic">antiemetic</a>, or anti-nausea, medications have been made in the beginning of the 21st century. Patients will often receive a combination of 5-HT<sub>3</sub> receptor antagonists (e.g. <a href="../../../o/n/d/Ondansetron.html" title="Ondansetron">ondansetron</a>), <a href="../../../c/o/r/Corticosteroid.html" title="Corticosteroid">corticosteroids</a>, and <a href="../../../b/e/n/Benzodiazepine.html" title="Benzodiazepine">benzodiazepines</a> before chemotherapy to prevent nausea. These medicines are also effective after nausea develops, as are <a href="../../../p/h/e/Phenothiazine.html" title="Phenothiazine">phenothiazines</a>. Each person's sensitivity to nausea and vomiting varies. Overall, while patients often experience some mild to moderate nausea, severe nausea or vomiting are uncommon with ABVD.</p>
<p><a name="Growth_factors" id="Growth_factors"></a></p>
<h3><span class="editsection">[<a href="../../../a/b/v/ABVD_12ba.html" title="Edit section: Growth factors">edit</a>]</span> <span class="mw-headline">Growth factors</span></h3>
<p>Blood growth factors are medicines that stimulate the <a href="../../../b/o/n/Bone_marrow.html" title="Bone marrow">bone marrow</a> to produce more of a certain kind of <a href="../../../b/l/o/Blood_cell.html" title="Blood cell">blood cell</a>. Commonly used examples include <a href="../../../g/-/c/G-CSF_179f.html" title="G-CSF">G-CSF</a> and <a href="../../../e/r/y/Erythropoietin.html" title="Erythropoietin">erythropoietin</a>. These drugs are sometimes used with ABVD to prevent <a href="../../../n/e/u/Neutropenia.html" title="Neutropenia">neutropenia</a> (low <a href="../../../w/h/i/White_blood_cell.html" title="White blood cell">white blood cell</a> count) and <a href="../../../a/n/e/Anemia.html" title="Anemia">anemia</a> related to the chemotherapy, although their use is not universal.</p>
<p><a name="References" id="References"></a></p>
<h2><span class="editsection">[<a href="../../../a/b/v/ABVD_12ba.html" title="Edit section: References">edit</a>]</span> <span class="mw-headline">References</span></h2>
<div class="references-small">
<ol class="references">
<li id="_note-0"><b><a href="#_ref-0" title="">^</a></b> <cite style="font-style:normal">DeVita V, Simon R, Hubbard S, Young R, Berard C, Moxley J, Frei E, Carbone P, Canellos G (1980). "Curability of advanced Hodgkin's disease with chemotherapy. Long-term follow-up of MOPP-treated patients at the National Cancer Institute.". <i>Ann Intern Med</i> <b>92</b> (5): 587-95. <a href="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=6892984" class="external" title="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=6892984">PMID 6892984</a>.</cite><span class="Z3988" title="ctx_ver=Z39.88-2004&amp;rft_val_fmt=info%3Aofi%2Ffmt%3Akev%3Amtx%3Ajournal&amp;rft.atitle=Curability+of+advanced+Hodgkin%27s+disease+with+chemotherapy.+Long-term+follow-up+of+MOPP-treated+patients+at+the+National+Cancer+Institute.&amp;rft.title=Ann+Intern+Med&amp;rft.jtitle=Ann+Intern+Med&amp;rft.date=1980&amp;rft.volume=92&amp;rft.issue=5&amp;rft.au=DeVita+V%2C+Simon+R%2C+Hubbard+S%2C+Young+R%2C+Berard+C%2C+Moxley+J%2C+Frei+E%2C+Carbone+P%2C+Canellos+G&amp;rft.pages=587-95">&#160;</span></li>
<li id="_note-1"><b><a href="#_ref-1" title="">^</a></b> <cite style="font-style:normal">Longo D, Young R, Wesley M, Hubbard S, Duffey P, Jaffe E, DeVita V (1986). "Twenty years of MOPP therapy for Hodgkin's disease.". <i>J Clin Oncol</i> <b>4</b> (9): 1295-306. <a href="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=3528400" class="external" title="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=3528400">PMID 3528400</a>.</cite><span class="Z3988" title="ctx_ver=Z39.88-2004&amp;rft_val_fmt=info%3Aofi%2Ffmt%3Akev%3Amtx%3Ajournal&amp;rft.atitle=Twenty+years+of+MOPP+therapy+for+Hodgkin%27s+disease.&amp;rft.title=J+Clin+Oncol&amp;rft.jtitle=J+Clin+Oncol&amp;rft.date=1986&amp;rft.volume=4&amp;rft.issue=9&amp;rft.au=Longo+D%2C+Young+R%2C+Wesley+M%2C+Hubbard+S%2C+Duffey+P%2C+Jaffe+E%2C+DeVita+V&amp;rft.pages=1295-306">&#160;</span></li>
<li id="_note-2"><b><a href="#_ref-2" title="">^</a></b> <cite style="font-style:normal">Kaldor J, Day N, Clarke E, Van Leeuwen F, Henry-Amar M, Fiorentino M, Bell J, Pedersen D, Band P, Assouline D (1990). "Leukemia following Hodgkin's disease.". <i>N Engl J Med</i> <b>322</b> (1): 7-13. <a href="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=2403650" class="external" title="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=2403650">PMID 2403650</a>.</cite><span class="Z3988" title="ctx_ver=Z39.88-2004&amp;rft_val_fmt=info%3Aofi%2Ffmt%3Akev%3Amtx%3Ajournal&amp;rft.atitle=Leukemia+following+Hodgkin%27s+disease.&amp;rft.title=N+Engl+J+Med&amp;rft.jtitle=N+Engl+J+Med&amp;rft.date=1990&amp;rft.volume=322&amp;rft.issue=1&amp;rft.au=Kaldor+J%2C+Day+N%2C+Clarke+E%2C+Van+Leeuwen+F%2C+Henry-Amar+M%2C+Fiorentino+M%2C+Bell+J%2C+Pedersen+D%2C+Band+P%2C+Assouline+D&amp;rft.pages=7-13">&#160;</span></li>
<li id="_note-3"><b><a href="#_ref-3" title="">^</a></b> <cite style="font-style:normal">Bonadonna G, Zucali R, Monfardini S, De Lena M, Uslenghi C (1975). "Combination chemotherapy of Hodgkin's disease with adriamycin, bleomycin, vinblastine, and imidazole carboxamide versus MOPP.". <i>Cancer</i> <b>36</b> (1): 252-9. <a href="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=54209" class="external" title="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=54209">PMID 54209</a>.</cite><span class="Z3988" title="ctx_ver=Z39.88-2004&amp;rft_val_fmt=info%3Aofi%2Ffmt%3Akev%3Amtx%3Ajournal&amp;rft.atitle=Combination+chemotherapy+of+Hodgkin%27s+disease+with+adriamycin%2C+bleomycin%2C+vinblastine%2C+and+imidazole+carboxamide+versus+MOPP.&amp;rft.title=Cancer&amp;rft.jtitle=Cancer&amp;rft.date=1975&amp;rft.volume=36&amp;rft.issue=1&amp;rft.au=Bonadonna+G%2C+Zucali+R%2C+Monfardini+S%2C+De+Lena+M%2C+Uslenghi+C&amp;rft.pages=252-9">&#160;</span></li>
<li id="_note-4"><b><a href="#_ref-4" title="">^</a></b> <cite style="font-style:normal">Canellos G, Anderson J, Propert K, Nissen N, Cooper M, Henderson E, Green M, Gottlieb A, Peterson B (1992). "Chemotherapy of advanced Hodgkin's disease with MOPP, ABVD, or MOPP alternating with ABVD.". <i>N Engl J Med</i> <b>327</b> (21): 1478-84. <a href="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=1383821" class="external" title="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=1383821">PMID 1383821</a>.</cite><span class="Z3988" title="ctx_ver=Z39.88-2004&amp;rft_val_fmt=info%3Aofi%2Ffmt%3Akev%3Amtx%3Ajournal&amp;rft.atitle=Chemotherapy+of+advanced+Hodgkin%27s+disease+with+MOPP%2C+ABVD%2C+or+MOPP+alternating+with+ABVD.&amp;rft.title=N+Engl+J+Med&amp;rft.jtitle=N+Engl+J+Med&amp;rft.date=1992&amp;rft.volume=327&amp;rft.issue=21&amp;rft.au=Canellos+G%2C+Anderson+J%2C+Propert+K%2C+Nissen+N%2C+Cooper+M%2C+Henderson+E%2C+Green+M%2C+Gottlieb+A%2C+Peterson+B&amp;rft.pages=1478-84">&#160;</span></li>
<li id="_note-santoro">^ <a href="#_ref-santoro_0" title=""><sup><i><b>a</b></i></sup></a> <a href="#_ref-santoro_1" title=""><sup><i><b>b</b></i></sup></a> <a href="#_ref-santoro_2" title=""><sup><i><b>c</b></i></sup></a> <cite style="font-style:normal">Santoro A, Bonadonna G, Valagussa P, Zucali R, Viviani S, Villani F, Pagnoni A, Bonfante V, Musumeci R, Crippa F (1987). "Long-term results of combined chemotherapy-radiotherapy approach in Hodgkin's disease: superiority of ABVD plus radiotherapy versus MOPP plus radiotherapy.". <i>J Clin Oncol</i> <b>5</b> (1): 27-37. <a href="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=2433409" class="external" title="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=2433409">PMID 2433409</a>.</cite><span class="Z3988" title="ctx_ver=Z39.88-2004&amp;rft_val_fmt=info%3Aofi%2Ffmt%3Akev%3Amtx%3Ajournal&amp;rft.atitle=Long-term+results+of+combined+chemotherapy-radiotherapy+approach+in+Hodgkin%27s+disease%3A+superiority+of+ABVD+plus+radiotherapy+versus+MOPP+plus+radiotherapy.&amp;rft.title=J+Clin+Oncol&amp;rft.jtitle=J+Clin+Oncol&amp;rft.date=1987&amp;rft.volume=5&amp;rft.issue=1&amp;rft.au=Santoro+A%2C+Bonadonna+G%2C+Valagussa+P%2C+Zucali+R%2C+Viviani+S%2C+Villani+F%2C+Pagnoni+A%2C+Bonfante+V%2C+Musumeci+R%2C+Crippa+F&amp;rft.pages=27-37">&#160;</span></li>
<li id="_note-5"><b><a href="#_ref-5" title="">^</a></b> <cite style="font-style:normal">Viviani S, Santoro A, Ragni G, Bonfante V, Bestetti O, Bonadonna G (1985). "Gonadal toxicity after combination chemotherapy for Hodgkin's disease. Comparative results of MOPP vs ABVD.". <i>Eur J Cancer Clin Oncol</i> <b>21</b> (5): 601-5. <a href="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=2408897" class="external" title="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=2408897">PMID 2408897</a>.</cite><span class="Z3988" title="ctx_ver=Z39.88-2004&amp;rft_val_fmt=info%3Aofi%2Ffmt%3Akev%3Amtx%3Ajournal&amp;rft.atitle=Gonadal+toxicity+after+combination+chemotherapy+for+Hodgkin%27s+disease.+Comparative+results+of+MOPP+vs+ABVD.&amp;rft.title=Eur+J+Cancer+Clin+Oncol&amp;rft.jtitle=Eur+J+Cancer+Clin+Oncol&amp;rft.date=1985&amp;rft.volume=21&amp;rft.issue=5&amp;rft.au=Viviani+S%2C+Santoro+A%2C+Ragni+G%2C+Bonfante+V%2C+Bestetti+O%2C+Bonadonna+G&amp;rft.pages=601-5">&#160;</span></li>
<li id="_note-6"><b><a href="#_ref-6" title="">^</a></b> <cite style="font-style:normal">Anselmo A, Cartoni C, Bellantuono P, Maurizi-Enrici R, Aboulkair N, Ermini M. "Risk of infertility in patients with Hodgkin's disease treated with ABVD vs MOPP vs ABVD/MOPP.". <i>Haematologica</i> <b>75</b> (2): 155-8. <a href="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=1694156" class="external" title="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=1694156">PMID 1694156</a>.</cite><span class="Z3988" title="ctx_ver=Z39.88-2004&amp;rft_val_fmt=info%3Aofi%2Ffmt%3Akev%3Amtx%3Ajournal&amp;rft.atitle=Risk+of+infertility+in+patients+with+Hodgkin%27s+disease+treated+with+ABVD+vs+MOPP+vs+ABVD%2FMOPP.&amp;rft.title=Haematologica&amp;rft.jtitle=Haematologica&amp;rft.volume=75&amp;rft.issue=2&amp;rft.au=Anselmo+A%2C+Cartoni+C%2C+Bellantuono+P%2C+Maurizi-Enrici+R%2C+Aboulkair+N%2C+Ermini+M&amp;rft.pages=155-8">&#160;</span></li>
<li id="_note-7"><b><a href="#_ref-7" title="">^</a></b> <cite style="font-style:normal">Martin W, Ristow K, Habermann T, Colgan J, Witzig T, Ansell S (2005). "Bleomycin pulmonary toxicity has a negative impact on the outcome of patients with Hodgkin's lymphoma.". <i>J Clin Oncol</i> <b>23</b> (30): 7614-20. <a href="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=16186594" class="external" title="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=16186594">PMID 16186594</a>.</cite><span class="Z3988" title="ctx_ver=Z39.88-2004&amp;rft_val_fmt=info%3Aofi%2Ffmt%3Akev%3Amtx%3Ajournal&amp;rft.atitle=Bleomycin+pulmonary+toxicity+has+a+negative+impact+on+the+outcome+of+patients+with+Hodgkin%27s+lymphoma.&amp;rft.title=J+Clin+Oncol&amp;rft.jtitle=J+Clin+Oncol&amp;rft.date=2005&amp;rft.volume=23&amp;rft.issue=30&amp;rft.au=Martin+W%2C+Ristow+K%2C+Habermann+T%2C+Colgan+J%2C+Witzig+T%2C+Ansell+S&amp;rft.pages=7614-20">&#160;</span></li>
<li id="_note-8"><b><a href="#_ref-8" title="">^</a></b> <cite style="font-style:normal">Canellos G, Duggan D, Johnson J, Niedzwiecki D (2004). "How important is bleomycin in the adriamycin + bleomycin + vinblastine + dacarbazine regimen?". <i>J Clin Oncol</i> <b>22</b> (8): 1532-3. <a href="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=15084636" class="external" title="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=15084636">PMID 15084636</a>.</cite><span class="Z3988" title="ctx_ver=Z39.88-2004&amp;rft_val_fmt=info%3Aofi%2Ffmt%3Akev%3Amtx%3Ajournal&amp;rft.atitle=How+important+is+bleomycin+in+the+adriamycin+%2B+bleomycin+%2B+vinblastine+%2B+dacarbazine+regimen%3F&amp;rft.title=J+Clin+Oncol&amp;rft.jtitle=J+Clin+Oncol&amp;rft.date=2004&amp;rft.volume=22&amp;rft.issue=8&amp;rft.au=Canellos+G%2C+Duggan+D%2C+Johnson+J%2C+Niedzwiecki+D&amp;rft.pages=1532-3">&#160;</span></li>
<li id="_note-9"><b><a href="#_ref-9" title="">^</a></b> <cite style="font-style:normal">van Leeuwen F, Klokman W, Veer M, Hagenbeek A, Krol A, Vetter U, Schaapveld M, van Heerde P, Burgers J, Somers R, Aleman B (2000). "Long-term risk of second malignancy in survivors of Hodgkin's disease treated during adolescence or young adulthood.". <i>J Clin Oncol</i> <b>18</b> (3): 487-97. <a href="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=10653864" class="external" title="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=10653864">PMID 10653864</a>.</cite><span class="Z3988" title="ctx_ver=Z39.88-2004&amp;rft_val_fmt=info%3Aofi%2Ffmt%3Akev%3Amtx%3Ajournal&amp;rft.atitle=Long-term+risk+of+second+malignancy+in+survivors+of+Hodgkin%27s+disease+treated+during+adolescence+or+young+adulthood.&amp;rft.title=J+Clin+Oncol&amp;rft.jtitle=J+Clin+Oncol&amp;rft.date=2000&amp;rft.volume=18&amp;rft.issue=3&amp;rft.au=van+Leeuwen+F%2C+Klokman+W%2C+Veer+M%2C+Hagenbeek+A%2C+Krol+A%2C+Vetter+U%2C+Schaapveld+M%2C+van+Heerde+P%2C+Burgers+J%2C+Somers+R%2C+Aleman+B&amp;rft.pages=487-97">&#160;</span></li>
</ol>
</div>
<p><a name="See_also" id="See_also"></a></p>
<h2><span class="editsection">[<a href="../../../a/b/v/ABVD_12ba.html" title="Edit section: See also">edit</a>]</span> <span class="mw-headline">See also</span></h2>
<ul>
<li><a href="../../../s/t/a/Stanford_V_bb98.html" title="Stanford V">Stanford V</a></li>
</ul>
<p><a name="External_links" id="External_links"></a></p>
<h2><span class="editsection">[<a href="../../../a/b/v/ABVD_12ba.html" title="Edit section: External links">edit</a>]</span> <span class="mw-headline">External links</span></h2>
<ul>
<li><a href="http://www.cancer.org/docroot/CRI/content/CRI_2_4_1X_What_is_Hodgkins_disease_20.asp" class="external text" title="http://www.cancer.org/docroot/CRI/content/CRI_2_4_1X_What_is_Hodgkins_disease_20.asp" rel="nofollow">American Cancer Society Guide to Hodgkin's Disease</a></li>
<li><a href="http://www.cancer.gov/cancertopics/types/hodgkinslymphoma" class="external text" title="http://www.cancer.gov/cancertopics/types/hodgkinslymphoma" rel="nofollow">Hodgkin's Lymphoma Home Page</a> at the American <a href="../../../n/a/t/National_Cancer_Institute_eeb0.html" title="National Cancer Institute">National Cancer Institute</a></li>
<li><a href="http://www.lymphomainfo.net/hodgkins/timeline.html" class="external text" title="http://www.lymphomainfo.net/hodgkins/timeline.html" rel="nofollow">Timeline of discovery and treatment of Hodgkin's Lymphoma</a></li>
<li><a href="http://www.lymphomainfo.net/hodgkins/description.html" class="external text" title="http://www.lymphomainfo.net/hodgkins/description.html" rel="nofollow">Hodgkin's Lymphoma</a></li>
</ul>

<!-- 
Pre-expand include size: 55780 bytes
Post-expand include size: 23562 bytes
Template argument size: 18186 bytes
Maximum: 2048000 bytes
-->
<div class="printfooter">
Retrieved from "<a href="http://en.wikipedia.org../../../a/b/v/ABVD_12ba.html">http://en.wikipedia.org../../../a/b/v/ABVD_12ba.html</a>"</div>
	    <div id="catlinks"><p class='catlinks'><a href="../../../c/a/t/Special%7ECategories_101d.html" title="Special:Categories">Categories</a>: <span dir='ltr'><a href="../../../o/n/c/Category%7EOncology_7a32.html" title="Category:Oncology">Oncology</a></span> | <span dir='ltr'><a href="../../../c/a/n/Category%7ECancer_treatments_ae68.html" title="Category:Cancer treatments">Cancer treatments</a></span> | <span dir='ltr'><a href="../../../c/h/e/Category%7EChemotherapeutic_agents_0a44.html" title="Category:Chemotherapeutic agents">Chemotherapeutic agents</a></span></p></div>	    <!-- end content -->
	    <div class="visualClear"></div>
	  </div>
	</div>
      </div>
      <div id="column-one">
	<div id="p-cactions" class="portlet">
	  <h5>Views</h5>
	  <ul>
	    <li id="ca-nstab-main"
	       class="selected"	       ><a href="../../../a/b/v/ABVD_12ba.html">Article</a></li><li id="ca-talk"
	       	       ><a href="../../../a/b/v/Talk%7EABVD_ced6.html">Discussion</a></li><li id="ca-current"
	       	       ><a href="http://en.wikipedia.org/wiki/ABVD">Current revision</a></li>	  </ul>
	</div>
	<div class="portlet" id="p-logo">
	  <a style="background-image: url(../../../images/wiki-en.png);"
	    href="../../../index.html"
	    title="Main Page"></a>
	</div>
	<script type="text/javascript"> if (window.isMSIE55) fixalpha(); </script>
		<div class='portlet' id='p-navigation'>
	  <h5>Navigation</h5>
	  <div class='pBody'>
	    <ul>
	    	      <li id="n-Main-page"><a href="../../../index.html">Main page</a></li>
	     	      <li id="n-Contents"><a href="../../../c/o/n/Wikipedia%7EContents_3181.html">Contents</a></li>
	     	      <li id="n-Featured-content"><a href="../../../f/e/a/Wikipedia%7EFeatured_content_24ba.html">Featured content</a></li>
	     	      <li id="n-currentevents"><a href="../../../c/u/r/Portal%7ECurrent_events_bb60.html">Current events</a></li>
	     	    </ul>
	  </div>
	</div>
		<div class='portlet' id='p-interaction'>
	  <h5>interaction</h5>
	  <div class='pBody'>
	    <ul>
	    	      <li id="n-About-Wikipedia"><a href="../../../a/b/o/Wikipedia%7EAbout_8d82.html">About Wikipedia</a></li>
	     	      <li id="n-portal"><a href="../../../c/o/m/Wikipedia%7ECommunity_Portal_6a3c.html">Community portal</a></li>
	     	      <li id="n-contact"><a href="../../../c/o/n/Wikipedia%7EContact_us_afd6.html">Contact us</a></li>
	     	      <li id="n-sitesupport"><a href="http://wikimediafoundation.org/wiki/Fundraising">Make a donation</a></li>
	     	      <li id="n-help"><a href="../../../c/o/n/Help%7EContents_22de.html">Help</a></li>
	     	    </ul>
	  </div>
	</div>
		<div id="p-search" class="portlet">
	  <h5><label for="searchInput">Search</label></h5>
	  <div id="searchBody" class="pBody">
	    <form action="javascript:goToStatic(3)" id="searchform"><div>
	      <input id="searchInput" name="search" type="text"
	        accesskey="f" value="" />
	      <input type='submit' name="go" class="searchButton" id="searchGoButton"
	        value="Go" />
	    </div></form>
	  </div>
	</div>
	<div id="p-lang" class="portlet">
	  <h5>In other languages</h5>
	  <div class="pBody">
	    <ul>
	      	      <li>
	      <a href="../../../../de/a/b/v/ABVD-Schema_91ba.html">Deutsch</a>
	      </li>
	      	    </ul>
	  </div>
	</div>
	      </div><!-- end of the left (by default at least) column -->
      <div class="visualClear"></div>
      <div id="footer">
    <div id="f-poweredbyico"><a href="http://www.mediawiki.org/"><img src="../../../skins/common/images/poweredby_mediawiki_88x31.png" alt="Powered by MediaWiki" /></a></div>	<div id="f-copyrightico"><a href="http://wikimediafoundation.org/"><img src="../../../images/wikimedia-button.png" border="0" alt="Wikimedia Foundation"/></a></div>	<ul id="f-list">
	  	  	  <li id="f-credits">This page was last modified 19:30, 16 December 2006 by Wikipedia user <a href="../../../s/t/b/User%7ESTBotD_8c4f.html" title="User:STBotD">STBotD</a>. Based on work by Wikipedia user(s) <a href="../../../m/a/s/User%7EMastCell_1b0e.html" title="User:MastCell">MastCell</a>, <a href="../../../4/h/o/User%7E4hodmt.html" title="User:4hodmt">4hodmt</a>, <a href="../../../w/o/u/User%7EWouterstomp_b006.html" title="User:Wouterstomp">Wouterstomp</a> and <a href="../../../c/h/a/User%7EChavoguero_6394.html" title="User:Chavoguero">Chavoguero</a> and Anonymous user(s) of Wikipedia.</li>	  <li id="f-copyright">All text is available under the terms of the <a class='internal' href="../../../t/e/x/Wikipedia%7EText_of_the_GNU_Free_Documentation_License_702a.html" title="Wikipedia:Text of the GNU Free Documentation License">GNU Free Documentation License</a>. (See <b><a class='internal' href="../../../c/o/p/Wikipedia%7ECopyrights_92c4.html" title="Wikipedia:Copyrights">Copyrights</a></b> for details.) <br /> Wikipedia&reg; is a registered trademark of the <a href="http://www.wikimediafoundation.org">Wikimedia Foundation, Inc</a>., a US-registered <a class='internal' href="../../../5/0/1/501%28c%29.html#501.28c.29.283.29" title="501(c)(3)">501(c)(3)</a> <a href="http://wikimediafoundation.org/wiki/Deductibility_of_donations">tax-deductible</a> <a class='internal' href="../../../n/o/n/Non-profit_organization.html" title="Non-profit organization">nonprofit</a> <a href="../../../c/h/a/Charitable_organization.html" title="Charitable organization">charity</a>.<br /></li>	  <li id="f-about"><a href="../../../a/b/o/Wikipedia%7EAbout_8d82.html" title="Wikipedia:About">About Wikipedia</a></li>	  <li id="f-disclaimer"><a href="../../../g/e/n/Wikipedia%7EGeneral_disclaimer_3e44.html" title="Wikipedia:General disclaimer">Disclaimers</a></li>	  	</ul>
      </div>
    </div>
  </body>
</html>
